The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome

The ALPESTRIA-1 Phase 2 clinical study ( ) is an open-label, single arm, fixed dose escalation of the investigational drug Vonafexor. This study is a proof-of-concept trial of Vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome. The study aims to recruit 20 patients in the US and EU (France, Spain and Germany). NCT06425055 The first site for patient recruitment is now open in Idaho (US) and more sites will open in the coming weeks. More information about the study here: Patients Read next in 'Events' ERA, le 63ème congrès annuel de néphrologie européen 63rd ERA congress, the Annual Nephrology Congress in Europe J.P. Morgan week à San Francisco J.P. Morgan week in San Francisco ASN 2025 - American Society of Nephrology

The release as fetched from its publisher. enyopharma.com ↗